Stock VLA VALNEVA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:14 2024-04-26 am EDT 		5-day change 1st Jan Change
3.444 EUR -0.06% Intraday chart for Valneva -5.95% -27.03%
Apr. 11 Valneva: Deep Track Biotechnology Master holds less than 5% of the capital CF
Mar. 26 Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 233.7 704.9 2,574 861.1 655.1 478 - -
Enterprise Value (EV) 1 195.5 553.9 2,286 670.5 737.8 512.5 566 591.9
P/E ratio -129 x -10.9 x -32.7 x -5.02 x -6.47 x 23.3 x -41.7 x -18.4 x
Yield - - - - - - 0.29% -
Capitalization / Revenue 1.85 x 6.39 x 7.4 x 2.38 x 4.26 x 2.48 x 2.05 x 1.48 x
EV / Revenue 1.55 x 5.02 x 6.57 x 1.86 x 4.8 x 2.66 x 2.42 x 1.84 x
EV / EBITDA 25.1 x -12.3 x -48.5 x -9.69 x -11.3 x 9.52 x -22.8 x -228 x
EV / FCF -36.5 x 4.68 x -140 x -2.44 x -3.4 x -36.6 x -258 x 172 x
FCF Yield -2.74% 21.4% -0.71% -41% -29.4% -2.74% -0.39% 0.58%
Price to Book 1.73 x 9.09 x 15.1 x - - 2.18 x 4.07 x 4.83 x
Nbr of stocks (in thousands) 90,920 90,958 105,078 138,355 138,788 138,788 - -
Reference price 2 2.570 7.750 24.50 6.224 4.720 3.444 3.444 3.444
Announcement Date 2/27/20 2/25/21 2/3/22 3/23/23 3/21/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 126.2 110.3 348.1 361.3 153.7 192.4 233.7 322
EBITDA 1 7.8 -45.2 -47.1 -69.2 -65.24 53.82 -24.81 -2.591
EBIT 1 -0.811 -55.12 -61.4 -113.4 -82.09 31.72 -32.5 5.123
Operating Margin -0.64% -49.97% -17.64% -31.4% -53.4% 16.49% -13.91% 1.59%
Earnings before Tax (EBT) 1 -0.87 -65.3 -69.98 -144.8 -98.63 22.66 -33.85 -6.817
Net income 1 -1.7 -64.4 -73.4 -143.3 -101.4 25.44 -33.17 -15.29
Net margin -1.35% -58.39% -21.09% -39.66% -65.99% 13.22% -14.19% -4.75%
EPS 2 -0.0200 -0.7100 -0.7500 -1.240 -0.7300 0.1475 -0.0825 -0.1867
Free Cash Flow 1 -5.355 118.3 -16.27 -274.7 -217 -14.02 -2.198 3.439
FCF margin -4.24% 107.22% -4.67% -76.02% -141.16% -7.29% -0.94% 1.07%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - 0.0100 -
Announcement Date 2/27/20 2/25/21 2/3/22 3/23/23 3/21/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 47.91 22.3 278.3 21.8 71.4 93.2 156.7 111.4 33.51 40.19 38.07 41.9 66.6 37.95 43.24 52.22
EBITDA - - 12.54 -13.3 -122.7 - - - - - - - - - - -
EBIT 1 -21.93 -151.4 11.1 -18.4 -128.8 -147.2 93.32 -56.35 -16.57 -20.28 -22.21 -24.91 77.38 -20.01 -15.97 -15.64
Operating Margin -45.77% -679.15% 3.99% -84.4% -180.39% -157.94% 59.55% -50.58% -49.46% -50.46% -58.35% -59.45% 116.19% -52.71% -36.93% -29.96%
Earnings before Tax (EBT) - - - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - - - -
EPS 2 - - - - - - - - -0.1300 -0.1200 -0.2500 -0.2300 0.6000 -0.0900 -0.1200 -0.1100
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 8/4/20 11/18/21 2/3/22 5/5/22 8/11/22 8/11/22 11/10/22 3/23/23 5/4/23 9/21/23 11/9/23 3/21/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 82.7 34.5 88 114
Net Cash position 1 38.1 151 289 191 - - - -
Leverage (Debt/EBITDA) - - - - -1.268 x 0.6409 x -3.546 x -43.95 x
Free Cash Flow 1 -5.36 118 -16.3 -275 -217 -14 -2.2 3.44
ROE (net income / shareholders' equity) -1.25% -60.6% -59.2% -73.4% -58.3% 16% -37.9% -17.9%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.490 0.8500 1.620 - - 1.580 0.8500 0.7100
Cash Flow per Share 2 0.0600 0.9500 - -0.8600 - -0.1000 -0.1000 0.1000
Capex 1 10.5 18.9 92.2 29.2 14.2 13.9 11.7 9.32
Capex / Sales 8.32% 17.17% 26.49% 8.09% 9.26% 7.25% 4.99% 2.89%
Announcement Date 2/27/20 2/25/21 2/3/22 3/23/23 3/21/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Valneva

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.444 EUR
Average target price
8.95 EUR
Spread / Average Target
+159.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VALNEVA Stock Valneva
-27.03% 510M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VLA Stock
  4. Financials Valneva